Related Experiment Video
Updated: Jan 21, 2026

Optogenetic Activation of Afferent Pathways in Brain Slices and Modulation of Responses by Volatile Anesthetics
Published on: July 23, 2020
The estrogen pathway as a modulator of response to immunotherapy
Maria A Velez1, Timothy F Burns2,3,4, Laura P Stabile2,4
1Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Abstract:
Lung cancer is the leading cause of cancer deaths worldwide, with a 5-year survival rate of about 18%. Thus, there is a great need for novel therapeutic approaches to treat non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have improved outcomes for a subset of patients, especially those with high programmed death-ligand 1 expression and/or high tumor mutational burden, but have failed in the majority of patients. Increasing evidence suggests that the estrogen signaling pathway may be a therapeutic target in metastatic NSCLC and that the estrogen pathway may play a role in sex-based responses to ICIs. This report will review the epidemiologic, preclinical and clinical data on the estrogen pathway in NSCLC, its implications in sex-based responses to ICIs and the potential use of antiestrogen therapy in combination with ICIs.
Insights
Estrogen signaling in non-small cell lung cancer (NSCLC) may impact treatment outcomes and sex-based responses to immune checkpoint inhibitors (ICIs). Targeting estrogen pathways could offer new therapeutic strategies for NSCLC patients.
Area of Science:
- Oncology
- Immunology
- Endocrinology
Background:
- Lung cancer remains a leading cause of cancer mortality globally, with limited treatment efficacy for many patients.
- Immune checkpoint inhibitors (ICIs) show promise but benefit only a subset of non-small cell lung cancer (NSCLC) patients.
- The estrogen signaling pathway is increasingly implicated in NSCLC development and treatment response.
Purpose of the Study:
- To review current data on the estrogen pathway in NSCLC.
- To explore the role of estrogen signaling in sex-based differences in response to ICIs.
- To evaluate the potential of antiestrogen therapy combined with ICIs for NSCLC treatment.
Main Methods:
- Review of epidemiologic data.
- Analysis of preclinical studies.
- Evaluation of clinical trial outcomes.
Main Results:
- Evidence suggests estrogen signaling influences NSCLC progression.
- The estrogen pathway may mediate differential responses to ICIs between sexes.
- Antiestrogen therapies are being investigated for synergistic effects with ICIs.
Conclusions:
- The estrogen pathway represents a potential therapeutic target in NSCLC.
- Understanding estrogen's role could personalize ICI therapy and improve outcomes.
- Combination therapy with antiestrogens and ICIs warrants further clinical investigation.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Other Glycolytic Pathways
Respiration Pathways
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking...
ER Retrieval Pathway
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...

